Early clinical development: Evaluation of drug-induced torsades de pointes risk

Pharmacology and Therapeutics

Volumn 119, Issue 2, 2008, Pages 210-214

  Vik, Torbjorn ^a   Pollard, Chris ^b   Sager, Philip ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c CardioDx Inc   (United States)

Author keywords

Early clinical development; Moxifloxacin; Torsades de pointes liability; TQT

Indexed keywords

KETOCONAZOLE; MOXIFLOXACIN; PENTOBARBITAL; PRENYLAMINE; QUINIDINE; RANOLAZINE; TERFENADINE; VERAPAMIL;

CARDIOVASCULAR RISK; DRUG DEVELOPMENT; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG SAFETY; ELECTROCARDIOGRAM; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; MULTIPLE DRUG DOSE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SYNCOPE; TORSADE DES POINTES;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; TORSADES DE POINTES; TOXICITY TESTS;

EID: 50249105403     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.05.006     Document Type: Review

References (30)

1. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24 (2003) 619-625
2. Belardinelli L., Shryock J.C., Wu L., and Song Y. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm 2 (2005) S16-S22
3. Bloomfield D., Kost J., Ghosh K., Hreniuk, D., Hickey L., Guitierrez M., et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther (2008)
4. Cordes J.S., Sun S., Lloyd D.B., Bradley J.A., Opsahl A.C., Tengowski M.W., et al. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145 (2005) 15-23
5. Darpo B., and Sager P. Design of the "Thorough QT Study". Clin Pharmacol Ther 83 (2008) 529
6. Dessertenne F. La tachycardie ventriculaire a deux foyer opposes variables. Archive des maladies du coeur et des vaisseaux 59 (1966) 263-272
7. Ficker E., Kurychev Y.A., Dennis A.T., Obejero-Paz C., Wang L., Hawryluk P., et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66 (2004) 33-44
8. Garnett C.E., Beasley N., Bhattaram V.A., Jadhav P.R., Madabushi R., Stockbridge N., et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48 (2008) 13-18
9. Hammond T.G., and Pollard C.E. Use of in vitro methods to predict QT prolongation. Toxicol Appl Pharmacol 207 (2005) 446-450
10. Hondeghem L. "Is QT prolongation always intrinsically arrhythmogenic, or intrinsically antiarrhythmic?" British Society for Cardiovascular Research, The QT interval and drug-induced torsades de pointes (2007, 24-Sep)
11. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., and Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269 (1993) 1513-1518
12. ICH E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarhythmic Potential for Non-Antiarrhythmic Drugs (2005). http://www.ich.org/LOB/media/MEDIA1476.pdf Web page: www.ich.org/LOB/media/MEDIA1476.pdf
13. ICH S7B. The Nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by Human pharmaceuticals (2005). http://www.ich.org/LOB/media/MEDIA2192.pdf Web page: www.ich.org/LOB/media/MEDIA2192.pdf
14. Jervell A., and Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT-interval, and sudden death. Am Heart J 54 (1957) 59-68
15. Levine S.A., and Woodworth C.R. Congenital deaf mutism, prolonged QT-interval, syncopal attacks, and sudden death. N Eng J Med 259 (1958) 412-417
16. Li L., Sager P., Birmingham B., and Caplan R. Drug-induced changes in heart rate. DIA QT Meeting 2008 (2008)
17. Malik M., Färbom P., Batchvarov V., Hnatkova K., and Camm A.J. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87 3 (2002) 220-228
18. Malik M. Problems of heart rate correction in the assessment of drug-induced QT interval prolongation. J Cardiovasc Electr 12 (2001) 411-420
19. McMahon N., Pollard C.E., Hammond T.G., and Valentin J.-P. Cardiovascular safety pharmacology. In: Sietsema W.K., and Schwen R. (Eds). Nonclinical drug safety assessment: practical considerations for successful registration (2007) 87-123 Falls Church, USA: FDA News
20. Mitcheson J.S., and Perry M.D. Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Dev 6 (2003) 667-674
21. Newbold P., Sanders N., and Reele S.B. Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval. Br J Clin Pharmacol 63 3 (2007) 279-287
22. Patterson, S. on behalf of Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. (2005) Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations. Drug Inf J. 39, 243-265.
23. Pollard, C. E., Valentin, J. -P. & Hammond, T. G. (in press). Strategies to reduce the risk of drug-induced QT interval prolongation: A pharmaceutical company perspective. Br J Pharmacol (2008 May 26, Electronic publication ahead of print).
24. Priest B.T., Swensen A.M., and McManus O.B. Automated electrophysiology in drug discovery. Curr Pharm Des 13 (2007) 2325-2337
25. Products C.f.P.M. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. December 17 (1997)
26. Romano C., Gemme G., and Pongiglione R. Aritmie Cardiache Rare dell'eta' Pedriatrica. II. Accessi sincopali per fibrillazione ventricolare parossistica. (Presentazione del primo caso della letteratura pediatrica Italiana). La Clinica Pediatrica (Bologna), Sep vol. 45 (1963) 656-683
27. Sager, P. T. (in press). Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br J Pharmacol (2008 Jun 9, Electronic publication ahead of print).
28. Sager P.T., Nebout T., and Darpo B. ICH E14: A new regulatory guidance on the clinical evaluation of QT/QTc internal prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Drug Inf J 39 (2005) 387-394
29. Seltzer A., and Wray H.W. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964) 17-26
30. Ward O.C. A new familial cardiac syndrome in children. J Irish Med Assoc 54 (1964) 103-106